支气管哮喘患者CysLT1受体基因mRNA表达水平与CysLT1受体拮抗剂疗效的相关性分析  

Correlation analysis between CysLT1 receptor gene mRNA expression level and CysLT1 receptor antagonist efficacy in bronchial asthma patients

作　　者：黄琳惠[1] 董文[1] HUANG Linhui;DONG Wen(Department of Respiratory and Critical Medicine,Hainan People′s Hospital,Haikou,Hainan 570311,China)

机构地区：[1]海南省人民医院呼吸与危重症医学科

出　　处：《检验医学与临床》2020年第3期305-308,共4页Laboratory Medicine and Clinic

基　　金：海南省自然科学基金项目(30842)

摘　　要：目的探讨支气管哮喘患者半胱氨酰白三烯(CysLTs)受体基因mRNA表达水平与半胱氨酰白三烯受体(CysLT1受体)拮抗剂疗效的相关性。方法选取2016年2月至2018年3月于该院门诊就诊的84例支气管哮喘患者,根据孟鲁司特治疗1周后达到最低药物有效治疗浓度的标准确定最终入组人数,患者继续服用4周。计录并比较有效组、无效组患者β2受体激动剂用量、哮喘控制测试(ACT)评分、尿白三烯E4(LTE4)、1秒用力呼气容积(FEV1)、免疫球蛋白(Ig)E与呼气峰流速(PEF)等指标水平。分析CysLT1受体基因mRNA与以上指标的相关性。结果共78例患者完成试验,治疗后总有效率为51.28%(40/78)。有效组与无效组患者年龄,治疗前FEV1、PEF、IgE、ACT评分、β2受体激动剂用量,病程差异均无统计学意义(P>0.05)。有效组CysLT1受体基因mRNA、尿LTE4水平均高于无效组(P<0.05)。有效组治疗后PEF、FEV1、ACT评分上升,β2受体激动剂用量、尿LTE4水平下降,差异有统计学意义(P<0.05)。CysLT1受体基因mRNA水平与IgE、FEV1无相关性(P>0.05),与PEF呈负相关,与尿LTE4呈正相关(P<0.05)。结论支气管哮喘患者CysLT1受体基因mRNA的表达水平与CysLT1受体拮抗剂的疗效具有相关性,CysLT1受体拮抗剂可以有效改善症状,值得推广使用。Objective To investigate the relationship between the expression level of cysteinyl leukotrienes(CysLTs)receptor gene mRNA and the efficacy of CysLT1 receptor antagonist in bronchial asthma patients and its clinical value.Methods Eighty-four patients with bronchial asthma from February 2016 to March 2018 were collected.The final enrollment was determined according to whether the lowest effective therapeutic concentration of montelukast could be achieved after one week of montelukast treatment.After that,the patients continued to take montelukast for 4 weeks.Theβ2 receptor agonist dosing,asthma control test(ACT)score,urinary leukotriene E4(LTE4)and forced expiratory volume(FEV1),immunoglobulin(Ig)E,peak expiratory flow rate(PEF)were recorded and compared.The correlation between CysLT1 receptor gene mRNA and other factors were explored.Results A total of 78 patients completed the experiment,the total effective rate after treatment was 51.28%(40/78);there was no statistical difference between the effective group and the ineffective group in age,FEV1,PEF,IgE,ACT score,β2 receptor agonist dosage,and disease duration(P>0.05).The CysLT1 mRNA and urinary LTE4 were significantly different between the two groups(P<0.05).The CysLT1 mRNA and urinary LTE4 in effective group were higher than those in ineffective group.After treatment,PEF,FEV1 index and ACT score increased,β2 receptor agonist dosage and urinary LTE4 decreased,the differences were statistically significant(P<0.05).There was no correlation between CysLT1 mRNA level and IgE and FEV1(P>0.05).CysLT1 receptor mRNA was negatively correlated with PEF and positively correlated with urine LTE4(P<0.05).Conclusion The expression level of CysLT1 receptor gene in bronchial asthma patients is related to the efficacy of CysLT1 receptor antagonist.CysLT1 receptor antagonist can effectively improve symptoms and is worthy of promotion.

关 键 词：支气管哮喘 半胱氨酰白三烯受体基因 半胱氨酰白三烯受体拮抗剂 肺功能 孟鲁司特 

分 类 号：R562.2[医药卫生—呼吸系统]